Get the Stockscreener App
209.75
0.52%
1.09
Pre-market:
208.79
-0.96
-0.46%
Davita Inc stock is traded at $209.75, with a volume of 824.76K.
It is up +0.52% in the last 24 hours and up +5.01% over the past month.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
See More
Previous Close:
$208.66
Open:
$207.93
24h Volume:
824.76K
Relative Volume:
0.97
Market Cap:
$13.46B
Revenue:
$13.84B
Net Income/Loss:
$1.10B
P/E Ratio:
20.13
EPS:
10.4185
Net Cash Flow:
$1.49B
1W Performance:
+9.20%
1M Performance:
+5.01%
6M Performance:
+74.72%
1Y Performance:
+54.09%
1-Day Range:
$204.98
$210.59
1-Week Range:
$193.39
$211.80
52-Week Range:
$101.00
$211.80
Davita Inc Stock (DVA) Company Profile
Name
Davita Inc
Sector
Industry
Phone
310-536-2668
Address
2000 16TH STREET, DENVER, CO
Compare DVA vs HCA, THC, FMS, EHC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
209.75 | 13.46B | 13.84B | 1.10B | 1.49B | 10.42 |
HCA
Hca Healthcare Inc
|
389.97 | 86.51B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
179.11 | 15.43B | 21.46B | 2.65B | 3.35B | 19.23 |
FMS
Fresenius Medical Care Ag Adr
|
23.45 | 12.60B | 22.44B | 1.35B | 2.03B | 1.9002 |
EHC
Encompass Health Corp
|
99.36 | 9.86B | 6.07B | 793.80M | 464.40M | 5.9914 |
Davita Inc Stock (DVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Aug-07-23 | Upgrade | UBS | Neutral → Buy |
| Nov-01-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-31-22 | Downgrade | UBS | Buy → Neutral |
| Aug-19-22 | Resumed | UBS | Buy |
| Jun-21-22 | Reiterated | BofA Securities | Underperform |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-12-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-26-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-05-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-24-20 | Upgrade | Goldman | Neutral → Buy |
| Nov-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-25-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-11-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-26-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-19 | Upgrade | UBS | Sell → Neutral |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Dec-14-18 | Initiated | Barclays | Overweight |
| Nov-28-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-16-18 | Initiated | UBS | Sell |
| Nov-08-18 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Sep-13-18 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-04-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-12-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-11-17 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-17 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-17 | Downgrade | Jefferies | Buy → Hold |
| Dec-13-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Davita Inc Stock (DVA) Latest News
5-Day Rally Sends DaVita Stock Up 9.2% - Trefis
Expanded access, DaVita Patient-Facing Mobile App enters next phase of kidney care - AD HOC NEWS
DaVita vs. Encompass Health: Comparing Steady Patient Volumes and Growth RatesNews and Statistics - IndexBox
DaVita vs. Encompass Health: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
DaVita Inc. Stock (US23918K1088): Stock in focus after chart signals and a long-term return snapshot - AD HOC NEWS
DaVita gains 21.4% in three months: How should you play the stock? - MSN
DaVita Inc. Stock (US23918K1088): Valuation picture draws attention after recent gains - AD HOC NEWS
DaVita expands comprehensive kidney care through dialysis services - MSN
DaVita stock gains from integrated kidney care and CKCC progress - MSN
DaVita (DVA) Stock After 82% YTD Surge Is The Price Still Justified - Yahoo Finance
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
DaVita Inc (DVA) News, Articles, Events & Latest Updates - Stocktwits
DaVita Inc. Stock (US23918K1088): valuation metrics in focus for US dialysis provider - AD HOC NEWS
DaVita, SCA, USPI defeat class certification bid in US no-poach litigation - MLex
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
DaVita HealthCare (DVA) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance
DaVita Stock Gains From Integrated Kidney Care and CKCC Progress - TradingView
Are Investors Undervaluing DaVita (DVA) Right Now? - Yahoo Finance
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, LifeStance Health and Aveanna Healthcare - Yahoo Finance
DaVita’s US$500 Million Term Loan Reshapes Debt And Liquidity Profile - Yahoo Finance
DaVita Inc. $DVA Stake Lifted by Los Angeles Capital Management LLC - MarketBeat
A Look at DaVita Inc (DVA) After 3.2% Gain -- GF Value $172.98 v - GuruFocus
DaVita Expands Term Loan Facility, Enhancing Capital Flexibility - The Globe and Mail
Best Growth Stocks to Buy for June 9th - Yahoo! Finance Canada
Best Value Stocks to Buy for June 9th - Yahoo Finance Singapore
DaVita Inc. (DVA) Announces Ninth Amendment to Credit Agreement - GuruFocus
DavitaEnters Ninth Amendment To Credit Agreement With Jpmorgan On June 8, 2026SEC Filing - TradingView
DaVita Secures $500 Million Incremental Term Loan B-2 Under Credit Facility With JPMorgan - TradingView
DaVita Inc. Enters into Ninth Amendment to Credit Agreement for $500 Million Incremental Tranche B-2 Term Loan - marketscreener.com
DaVita Inc. (DVA) Maintains Strong Buy Rating for 120 Days - GuruFocus
MOTheR Trial: Advancing Middle-Molecule Clearance - DaVita Newsroom
Norges Bank Takes Position in DaVita Inc. $DVA - MarketBeat
DaVita Inc. $DVA Shares Purchased by Northwestern Mutual Wealth Management Co. - MarketBeat
Bull of the day: DaVita Inc. (DVA) - MSN
BI Asset Management Fondsmaeglerselskab A S Purchases 33,394 Shares of DaVita Inc. $DVA - MarketBeat
Asset turnover of DaVita Inc. – XETR:TRL - TradingView
Cash per share of DaVita Inc. – XETR:TRL - TradingView
Long term debt to total assets ratio of DaVita Inc. – XETR:TRL - TradingView
EBITDA per share of DaVita Inc. – XETR:TRL - TradingView
DaVita Inc. Cash Flow – XETR:TRL - TradingView
DaVita Inc. Statistics – XETR:TRL - TradingView
Assessing DaVita (DVA) Valuation After Strong Q1 2026 Beat And Upgraded Guidance - Yahoo Finance
Nomura Asset Management Co. Ltd. Sells 16,576 Shares of DaVita Inc. $DVA - MarketBeat
Why is DaVita HealthCare Partners stock surging today? - Investing.com
DaVita Inc stock (US23804L1035): Q1 2026 revenue tops estimates while valuation stays in focus - AD HOC NEWS
BofA raises DaVita stock price target to $145 on Q1 beat - Investing.com
DaVita Q1 2026 Earnings: Outpatient and Specialty Care Sector ReviewNews and Statistics - IndexBox
Q1 Earnings Highs And Lows: DaVita (NYSE:DVA) Vs The Rest Of The Outpatient & Specialty Care Stocks - Yahoo Finance
Why is DaVita HealthCare Partners stock surging today? By Investing.com - Investing.com UK
DaVita Inc. stock underperforms Thursday when compared to competitors - MarketWatch
The Sound of a Second Chance: DaVita Patients Celebrate Receiving Their Kidney Transplant - DaVita Newsroom
Davita Inc Stock (DVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.87%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):